The role of abiraterone in the management of metastatic castration-resistant prostate cancer - Abstract

Prostate cancer is the most common solid-organ cancer affecting the male population.

Men with metastatic prostate cancer treated with androgen ablation therapy often respond rapidly, with improvement in bone pain and decreases in serum prostate-specific antigen. However, almost all patients progress to the castrate-resistant state and until recently chemotherapy was the only treatment available with proven survival benefit. Abiraterone is a new class of anti-androgen with proven survival benefit post-chemotherapy. In this review we discuss the characteristics of abiraterone and the clinical trials that led to its approval for the treatment of patients with prostate cancer.

Written by:
Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M. Are you the author?
Department of Urology, Northampton General Hospital, Northampton, UK.

Reference: Expert Rev Anticancer Ther. 2012 Apr;12(4):429-37.
doi: 10.1586/era.12.12

PubMed Abstract
PMID: 22500680 Prostate Cancer Section